23 February 2010
Two oral presentations at the 17th Conference on Retroviruses and Opportunistic Infections (CROI) highlighted further results from the DART trial.
The first explored the risk of getting different HIV-related events and dying according to the CD4 cell count (a measure of the body's ability to fight HIV).
The second investigated how much CD4 cell counts increased over 5 years on anti-HIV drugs.
MRC Freedom of Information | UCL Freedom of Information
©2014 MRC Clinical Trials Unit at UCL.